Literature DB >> 32371841

Manifestations of pulmonary aspergillosis in pediatrics.

Archana Chacko1, Richard B Moss2.   

Abstract

PURPOSE OF REVIEW: Aspergillus spp. cause a clinical spectrum of disease with severity of disease dependent on degree of immune compromise, nature and intensity of inflammatory host response, and/or underlying lung disease. Chronic pulmonary aspergillosis encompasses a spectrum of diseases including aspergilloma, Aspergillus nodules, chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, and subacute invasive pulmonary aspergillosis. Allergic bronchopulmonary aspergillosis (ABPA) paradoxically is an immune hypersensitivity manifestation in the lungs that almost always occurs in the setting of underlying asthma or cystic fibrosis. These chronic Aspergillus conditions are now becoming more prevalent than invasive Aspergillus, thus it is important to be aware of the current literature of these conditions. RECENT
FINDINGS: High-level research assessing the clinical significance and treatment options of these chronic diseases are lacking. Recent literature suggests colonization is antecedent for local airway infection (Aspergillus bronchitis), chronic or allergic bronchopulmonary disease, or invasive and potentially disseminated disease. There have been few advances in assessment of treatment of ABPA.
SUMMARY: Research assessing the clinical significance and treatment options is currently needed.

Entities:  

Mesh:

Year:  2020        PMID: 32371841     DOI: 10.1097/MOP.0000000000000898

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  2 in total

1.  Chronic cavitary pulmonary aspergillosis in an immunocompetent child.

Authors:  Adeyinka A Davies; Ireti A Adegbite; Patricia E Akintan; Usman O Ibrahim; Abiola O Adekoya; Rita O Oladele
Journal:  Med Mycol Case Rep       Date:  2022-07-14

Review 2.  Do not forget asthma comorbidities in pediatric severe asthma!

Authors:  Lucia Ronco; Anna Folino; Manuela Goia; Benedetta Crida; Irene Esposito; Elisabetta Bignamini
Journal:  Front Pediatr       Date:  2022-07-29       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.